To read the full story, subscribe or sign in.

DR-10601 shows promise for the treatment of type 2 diabetes and obesity in preclinical models

Dec. 10, 2019

BioWorld Science Endocrine/metabolic

Today's news in brief

BioWorld

BioWorld briefs for Nov. 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 13, 2025.

Deal handshake with coin, chart background

ABL Bio’s Grabody lands second $2.6B deal, this time with Lilly

BioWorld

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple therapeutics using the Grabody-B platform....

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld Science

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...